Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Erenumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43893   clinical trials with a EudraCT protocol, of which   7300   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Erenumab. Displaying page 1 of 1.
    EudraCT Number: 2019-002224-32 Sponsor Protocol Number: SYNCHRO Start Date*: 2019-11-12
    Sponsor Name:Fundació Hospital Universitari Vall d' Hebrón - Institut de Recerca (VHIR)
    Full Title: Sense, rhYhm & Networks: the study of how erenumab modulates CHROnic migraine
    Medical condition: Chronic migraine
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10066636 Chronic migraine LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000661-16 Sponsor Protocol Number: CGRP2020 Start Date*: 2020-06-18
    Sponsor Name:Rigshospitalet Glostrup
    Full Title: The effect of anti-calcitonin gene-related peptide (CGRP) receptor antibodies on the headache inducing properties of CGRP and cilostazol in migraine patients
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-002201-22 Sponsor Protocol Number: CAMG334ADE03 Start Date*: 2019-08-28
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Assessment of Prolonged safety and tOLerability of erenumab in migraine patients in a Long-term OpeN-label study (APOLLON)
    Medical condition: Migraine prophylaxis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002399-23 Sponsor Protocol Number: 20160354 Start Date*: 2019-06-18
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With C...
    Medical condition: Chronic migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) GB (GB - no longer in EU/EEA) DE (Ongoing) BE (Ongoing) PL (Ongoing) HU (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001820-36 Sponsor Protocol Number: CAMG334AES01 Start Date*: 2019-08-13
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A 12-month prospective, phase IIIb, multicenter, open-label clinical trial to assess health-related quality of life (HRQoL) in patients with chronic or high-frequency episodic migraine treated with...
    Medical condition: Study of Quality of life in subjects with chronic or high-frequency episodic migraine and associated comorbidities treated with erenumab
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002397-39 Sponsor Protocol Number: 20150125 Start Date*: 2019-06-14
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With E...
    Medical condition: Episodic migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FI (Completed) DE (Ongoing) BE (Ongoing) PL (Ongoing) HU (Prematurely Ended) IT (Ongoing) ES (Ongoing) PT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004399-16 Sponsor Protocol Number: CHERUB01 Start Date*: 2021-04-28
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Efficacy of erenumab in chronic cluster headache: A 10-week double-blind, randomized, placebo-controlled, multicentric trial
    Medical condition: chronic cluster headache
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10009698 Cluster headaches LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003943-46 Sponsor Protocol Number: 081018 Start Date*: 2019-01-17
    Sponsor Name:Danish Headache Center
    Full Title: An open label study to evaluate the efficacy and tolerability of erenumab in the prophylactic treatment of persistent headache attributed to mild traumatic injury to the head
    Medical condition: Post-traumatic headache
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10019222 Headache post-traumatic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-000943-15 Sponsor Protocol Number: CAMG334ADE01 Start Date*: 2019-01-24
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Randomized, double-blind, multicenter head-to-head study of erenumab against topiramate - migraine study to assess tolerability and efficacy in a patient-centered setting (HER-MES)
    Medical condition: Migraine prophylaxis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001228-20 Sponsor Protocol Number: CAMG334A2401 Start Date*: 2019-04-11
    Sponsor Name:Novartis Pharma AG
    Full Title: A 12-month prospective, randomized, interventional, global, multi-center, active-controlled study comparing sustained benefit of two treatment paradigms (erenumab qm vs. oral prophylactics) in adul...
    Medical condition: Migraine prevention
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) FI (Completed) GB (GB - no longer in EU/EEA) SK (Completed) PT (Completed) GR (Completed) PL (Completed) ES (Ongoing) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-004875-11 Sponsor Protocol Number: CAMG334AIT03 Start Date*: 2019-05-29
    Sponsor Name:NOVARTIS FARMA S.P.A.
    Full Title: A RandomizEd, double-blind, cross-over Study to assess Erenumab effecT on BRAIN networks function and structure in comparison to placebo in episodic migraine patients (RESET BRAIN)
    Medical condition: Episodic migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000592-36 Sponsor Protocol Number: CGRP&AMS01 Start Date*: 2023-07-10
    Sponsor Name:Universitätsklinikum Essen
    Full Title: Calcitonin Gene-Related Peptide Receptor Antagonists for Prevention of Acute Mountain Sickness
    Medical condition: Acute Mountain Sickness (AMS) is a constellation of symptoms (headache, anorexia, nausea, vomiting, lightheadedness, and fatigue) occuring in unacclimatized mountaineers ascending too fast, too high
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004863 10020045 High altitude illness LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003646-33 Sponsor Protocol Number: 20190008 Start Date*: 2020-06-24
    Sponsor Name:Amgen, Inc.
    Full Title: Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Ph...
    Medical condition: High frequency episodic migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) PT (Completed) HU (Completed) BG (Completed) CZ (Completed) IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003971-20 Sponsor Protocol Number: ROS031019 Start Date*: 2020-03-03
    Sponsor Name:Rigshospitalet Glostrup
    Full Title: An open label study to evaluate the efficacy and tolerability of erenumab in the management of persistent redness and flushing in rosacea
    Medical condition: Rosacea
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10039218 Rosacea PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-003342-16 Sponsor Protocol Number: 20170703 Start Date*: 2019-10-21
    Sponsor Name:Amgen Inc
    Full Title: A Phase 4, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Chronic Migraine and Medication Overuse Headache
    Medical condition: Chronic migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Ongoing) PL (Completed) PT (Completed) FI (Completed) HU (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-000848-95 Sponsor Protocol Number: 020119 Start Date*: 2019-07-29
    Sponsor Name:Dansk Hovedpine Center, Neurologisk Klinik, Rigshospitalet - Glostrup
    Full Title: A Placebo-Controlled, Double-Blind, Randomized, Proof-of-Concept Study to Evaluate the Efficacy and Tolerability of Erenumab in Patients with Trigeminal Neuralgia
    Medical condition: Trigeminal neuralgia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10044652 Trigeminal neuralgia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002331-28 Sponsor Protocol Number: 20190006 Start Date*: 2020-03-10
    Sponsor Name:Amgen Inc.
    Full Title: Biomarker and Genetic Predictors of Erenumab Treatment Response, a Phase 4 Investigational Open-label Study (INTERROGATE)
    Medical condition: Episodic or chronic migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) IS (Completed)
    Trial results: View results
    EudraCT Number: 2012-005331-90 Sponsor Protocol Number: 20120178 Start Date*: 2013-08-14
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention
    Medical condition: Prevention of episodic migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10027608 Migraine, unspecified LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) FI (Completed) NO (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-000923-15 Sponsor Protocol Number: 20160172 Start Date*: 2018-06-14
    Sponsor Name:Amgen
    Full Title: A Phase I, Randomized, Open-label, Multiple-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AMG 334 in Children and Adolescents With Migraine
    Medical condition: Migraine prevention
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2021-005246-15 Sponsor Protocol Number: BHV3000-315 Start Date*: 2022-08-23
    Sponsor Name:Biohaven Pharmaceuticals Holding Company Limited
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 years of age
    Medical condition: Acute Migraine (with or without aura)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    20.0 10029205 - Nervous system disorders 10027603 Migraine headaches HLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Ongoing) IT (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 04:55:05 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA